Literature DB >> 3871631

Differential effect of isolated placental isoferritins on in vitro T-lymphocyte function.

Y Matzner, A M Konijn, Z Shlomai, H Ben-Bassat.   

Abstract

The effect of isoferritins isolated from human term placenta on certain T-lymphocyte parameters was studied in vitro using normal human lymphocytes. These isoferritins differed in ion exchange affinity, isoelectric point, and subunit composition. Only the acidic isoferritins caused a marked suppression of phytohaemagglutinin (PHA) blastogenesis and the most acidic isoferritin ('Acid I') was suppressive at a concentration as low as 0.25 microgram/ml. All four isoferritins suppressed concanavalin A (Con A) blastogenesis in a similar concentration dependent manner, with maximum effect at an isoferritin concentration of 1 microgram/ml. Both basic and acidic isoferritins reduced the Con-A-capping phenomenon in normal lymphocytes at concentrations higher than 0.5 microgram/ml, but at 0.25 microgram/ml only the acidic isoferritin was effective. The above findings support our previous report concerning the suppressive effect of splenic ferritin on T-lymphocyte function in vitro and indicate that acidic isoferritins, which often predominate in malignancy, demonstrate a higher degree of immunosuppressive activity. Thus, acidic isoferritins may play a role in the development of abnormal lymphocyte function encountered in certain proliferative disorders.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3871631     DOI: 10.1111/j.1365-2141.1985.tb07331.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  10 in total

1.  T-cell mitogenesis stimulates the synthesis of a mRNA species coding for a 43-kDa peptide reactive with CM-H-9, a monoclonal antibody specific for placental isoferritin.

Authors:  C Moroz; N Shterman; B Kupfer; I Ginzburg
Journal:  Proc Natl Acad Sci U S A       Date:  1989-05       Impact factor: 11.205

2.  Placental isoferritin as a physiological downregulator of cellular immunoreactivity during pregnancy.

Authors:  L Sirota; B Kupfer; C Moroz
Journal:  Clin Exp Immunol       Date:  1989-08       Impact factor: 4.330

3.  Tissue ferritin concentration and prognosis in carcinoma of the breast.

Authors:  R E Weinstein; B H Bond; B K Silberberg; C B Vaughn; P Subbaiah; D R Pieper
Journal:  Breast Cancer Res Treat       Date:  1989-12       Impact factor: 4.872

4.  Elevated serum placental isoferritin in newly diagnosed type 1 (insulin-dependent) diabetes mellitus. A possible marker for identification of high risk subjects.

Authors:  S Assa; C Moroz
Journal:  Diabetologia       Date:  1990-09       Impact factor: 10.122

5.  Up-regulation of NKG2A inhibitory receptor on circulating NK cells contributes to transfusion-induced immunodepression in patients with β-thalassemia major.

Authors:  Yong Zou; Zhi-Xing Song; Ying Lu; Xiao-Li Liang; Qing Yuan; Si-Hong Liao; Jun-Jie Bao
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2016-07-28

6.  A kindred with Griscelli disease: spectrum of neurological involvement.

Authors:  H Hurvitz; R Gillis; S Klaus; A Klar; F Gross-Kieselstein; E Okon
Journal:  Eur J Pediatr       Date:  1993-05       Impact factor: 3.183

7.  Placental ferritin in coeliac disease: relation to clinical stage, origin, and possible role in the pathogenesis of malignancy.

Authors:  G Dinari; I Zahavi; H Marcus; C Moroz
Journal:  Gut       Date:  1991-09       Impact factor: 23.059

8.  The effect of iron (Fe3+) on the cloning efficiency of human memory T4+ lymphocytes.

Authors:  M F Good; D E Chapman; L W Powell; J W Halliday
Journal:  Clin Exp Immunol       Date:  1986-11       Impact factor: 4.330

9.  The effect of experimental iron-overload on splenic T cell function: analysis using cloning techniques.

Authors:  M F Good; D E Chapman; L W Powell; J W Halliday
Journal:  Clin Exp Immunol       Date:  1987-05       Impact factor: 4.330

10.  MRI-based evaluation of multiorgan iron overload is a predictor of adverse outcomes in pediatric patients undergoing allogeneic hematopoietic stem cell transplantation.

Authors:  Natalia Maximova; Massimo Gregori; Giulia Boz; Roberto Simeone; Davide Zanon; Giulia Schillani; Floriana Zennaro
Journal:  Oncotarget       Date:  2017-07-05
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.